Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Genomic and transcriptomic signatures of extramedullary multiple myeloma reveal possible drivers of therapeutic resistance

Catherine Duane, Tony O'Grady, Sahin Sarihan, Izabela Cymer, Michael O'Dwyer, Adam Roche, Philip Murphy, John Quinn, Siobhan Glavey

Blood (2025) 146 (Supplement 1): 2175.

https://doi.org/10.1182/blood-2025-2175

Published: 2025

Journal Articles

Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population

Blood (2025) 146 (Supplement 1): 4031.

https://doi.org/10.1182/blood-2025-4031

Published: 2025

Journal Articles

NK Cell States in Multiple Myeloma: Pathways to Novel Immunotherapies

Jacopo Umberto Verga, Eva Szegezdi, Pilib Ó Broin, Michael O'Dwyer, Micheál Ó Dálaigh, Wanshan Hu

Blood (2024) 144 (Supplement 1): 6857.

https://doi.org/10.1182/blood-2024-210297

Published: 2024

Journal Articles

Increased Expression of the Sialyltransferase Gene ST3GAL1 Predicts Lack of Sustained MRD Negativity and Increased Risk of Progression in Newly Diagnosed, Transplant Eligible Multiple Myeloma Patients in the Maintenance/Observation Phase of Cassiopeia Study

Michael O'Dwyer, Aideen Edele Ryan, Aoise O'Neill, Catherine Guerin-Charbonnel, Soraya Wuilleme, Jill Corre, Herve Avet Loiseau, Li Peng, Philippe Moreau, Stephane Minvielle

Blood (2024) 144 (Supplement 1): 250.

https://doi.org/10.1182/blood-2024-193955

Published: 2024

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Blood (2022) 140 (Supplement 1): 10150–10153.

https://doi.org/10.1182/blood-2022-163335

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Blood (2022) 140 (Supplement 1): 10133–10136.

https://doi.org/10.1182/blood-2022-163555

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Blood (2022) 140 (Supplement 1): 7297–7300.

https://doi.org/10.1182/blood-2022-163494

Published: 2022

Journal Articles

miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia

Camille Malouf, Eric T. B. Antunes, Michael O’Dwyer, Hélène Jakobczyk, Franziska Sahm, Sophie-Luise Landua, Richard A. Anderson, Abdenour Soufi, Christina Halsey, Katrin Ottersbach

Blood (2021) 138 (21): 2066–2092.

https://doi.org/10.1182/blood.2020006610

Published: 2021

Includes: Supplemental data

Journal Articles

Low Dose Cyclophosphamide in Combination with Elotuzumab - a Novel Immunotherapeutic Strategy for Multiple Myeloma

Claire L Feerick, Kevin Lynch, Janusz Krawczyk, Michael O'Dwyer, Aideen Ryan

Blood (2021) 138 (Supplement 1): 2664.

https://doi.org/10.1182/blood-2021-152432

Published: 2021

Journal Articles

Single Cell Transcriptomics Revealed Molecular Alterations in AML Cell Clusters Relevant to Refractory Disease at Relapse

Sarah Ennis, Alessandra Conforte, Sukhraj Pal Singh Dhami, Philippe Krebs, Michael O'Dwyer, Eva Szegezdi

Blood (2021) 138 (Supplement 1): 3316.

https://doi.org/10.1182/blood-2021-153910

Published: 2021

Journal Articles

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Blood (2018) 132 (Supplement 1): LBA-2.

https://doi.org/10.1182/blood-2018-120737

Published: 2018

Journal Articles

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Daniel J. DeAngelo, MD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, Anjali S. Advani, MD, Paula Marlton, MBBS, Michael O'Dwyer, MD, John L Magnani, PhD, Helen M. Thackray, MD, Pamela S. Becker, MD PhD

Blood (2017) 130 (Supplement 1): 894.

https://doi.org/10.1182/blood.V130.Suppl_1.894.894

Published: 2017

Journal Articles

Interleukin-6 Drives Multiple Myeloma Progression through Upregulating of CD147/Emmprin Expression and Its Sialylation

Yanmeng Wang, Rong Fan, Li Lei, PhD, Aiying Wang, Xiaman Wang, Shen Ying, Hongli Chen, Caoilfhionn Connolly, MD, Kim De Veirman, Aili He, MD, Karin Vanderkerken, PhD, Michael O'Dwyer, MD, Jinsong Hu, PhD

Blood (2017) 130 (Supplement 1): 3037.

https://doi.org/10.1182/blood.V130.Suppl_1.3037.3037

Published: 2017

Journal Articles

Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma

John Daly, MSc, Tony Duggan, BSc, Jinsong Hu, PhD, Alessandro Natoni, PhD, Subhashis Sarkar, PhD, Lucy Kirkham-McCarthy, MSc, Cian McEllistrim, MD, Janusz Krawczyk, MD, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 1799.

https://doi.org/10.1182/blood.V130.Suppl_1.1799.1799

Published: 2017

Journal Articles

Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP

Serika Naicker, BSc, PhD, Athina Rigalou, BSc MSc, Cian McEllistrim, MB, BCh, BAO, Alessandro Natoni, PhD, Christopher Chiu, Kate Sasser, PhD, Aideen Ryan, BSc,PhD, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 121.

https://doi.org/10.1182/blood.V130.Suppl_1.121.121

Published: 2017

Journal Articles

Mesenchymal Stromal Cell Sialylation Enhances Immune Suppression in Multiple Myeloma

Kevin Lynch, BSc, MSc, O'Malley Grace, BSc, Aideen Ryan, BSc,PhD, Thomas Ritter, BSc, PhD, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 124.

https://doi.org/10.1182/blood.V130.Suppl_1.124.124

Published: 2017

Journal Articles

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Cian McEllistrim, MD, Mary R Cahill, MD, Philip Murphy, PhD BPharm, Vitaliy Mykytiv, MD, John Quinn, Amanda Bray, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Grace Hirakata, Imelda Parker, Andres Hernando, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 3163.

https://doi.org/10.1182/blood.V130.Suppl_1.3163.3163

Published: 2017

Journal Articles

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Steven Coutre, MD, John C. Byrd, MD, Peter Hillmen, Jacqueline C. Barrientos, MD, Paul M. Barr, Stephen Devereux, PhD FRCP, FRCPath, Tadeusz Robak, MD PhD, Thomas J. Kipps, MD, PhD, Anna Schuh, MDPhD, Carol Moreno, MD, Richard R. Furman, Jan Burger, MD PhD, Michael O'Dwyer, MD, Paolo Ghia, Rudolph Valentino, PharmD, Samuel Suzuki, MS, MBA, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, Susan M. O'Brien, MD

Blood (2016) 128 (22): 4383.

https://doi.org/10.1182/blood.V128.22.4383.4383

Published: 2016

Journal Articles

Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2 TM )

Blood (2015) 126 (23): 495.

https://doi.org/10.1182/blood.V126.23.495.495

Published: 2015

Journal Articles

Estimating the Relative Effectiveness of Treatments in Relapsed/Refractory Multiple Myeloma through a Systematic Review and Network Meta-Analysis

Kai Ruggeri, PhD, Áine Maguire, MSc, Susanne Schmitz, PhD, Elisa Haller, MSc, Cathal Walsh, PhD, Jack Bowden, PhD, Isla Kuhn, Ayesha Khan, PhD, Gordon Cook, MD PhD, Michael O'Dwyer, MD

Blood (2015) 126 (23): 2103.

https://doi.org/10.1182/blood.V126.23.2103.2103

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genomic and transcriptomic signatures of extramedullary multiple myeloma reveal possible drivers of therapeutic resistance

Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population

NK Cell States in Multiple Myeloma: Pathways to Novel Immunotherapies

Increased Expression of the Sialyltransferase Gene ST3GAL1 Predicts Lack of Sustained MRD Negativity and Increased Risk of Progression in Newly Diagnosed, Transplant Eligible Multiple Myeloma Patients in the Maintenance/Observation Phase of Cassiopeia Study

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia

Low Dose Cyclophosphamide in Combination with Elotuzumab - a Novel Immunotherapeutic Strategy for Multiple Myeloma

Single Cell Transcriptomics Revealed Molecular Alterations in AML Cell Clusters Relevant to Refractory Disease at Relapse

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Interleukin-6 Drives Multiple Myeloma Progression through Upregulating of CD147/Emmprin Expression and Its Sialylation

Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma

Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP

Mesenchymal Stromal Cell Sialylation Enhances Immune Suppression in Multiple Myeloma

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2 TM )

Estimating the Relative Effectiveness of Treatments in Relapsed/Refractory Multiple Myeloma through a Systematic Review and Network Meta-Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only